L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer et al., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, N Engl J Med, vol.356, pp.459-68, 2007.

K. Zoi and N. Cross, Genomics of myeloproliferative neoplasms, J Clin Oncol, vol.35, pp.947-54, 2017.

Y. L. Wang, K. Vandris, A. Jones, N. Cross, C. P. Adriano et al., JAK2 mutations are present in all cases of polycythemia vera, Leukemia, vol.22, pp.1289-1289, 2008.

J. Grisouard, S. Li, L. Kubovcakova, T. N. Rao, S. C. Meyer et al., JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis, Blood, vol.128, pp.839-51, 2016.

H. Yao, Y. Ma, Z. Hong, L. Zhao, S. A. Monaghan et al., Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm, Leukemia, vol.31, pp.2122-2153, 2017.

A. L. Godfrey, E. Chen, C. E. Massie, Y. Silber, F. Pagano et al., STAT1 activation in association with JAK2 exon 12 mutations, Haematologica, vol.101, pp.15-19, 2015.

F. Passamonti, C. Elena, S. Schnittger, R. C. Skoda, A. R. Green et al., Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations, Blood, vol.117, pp.2813-2819, 2011.

A. Tefferi, S. Lavu, M. Mudireddy, T. L. Lasho, C. M. Finke et al., JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease, Am J Hematol, vol.93, pp.93-96, 2018.

B. Cassinat, C. Laguillier, C. Gardin, V. De-beco, S. Burcheri et al., Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?, Leukemia, vol.22, pp.452-455, 2007.

A. Alvarez-larran, A. Ancochea, A. Angona, C. Pedro, F. Garcia-pallarols et al., Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia, Haematologica, vol.97, pp.1704-1711, 2012.

A. Pardanani, T. L. Lasho, C. Finke, C. A. Hanson, and A. Tefferi, Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera, Leukemia, vol.21, pp.1960-1963, 2007.

E. Kouroupi, K. Zoi, N. Parquet, C. Zoi, J. Kiladjian et al., Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients: correspondence, Br J Haematol, vol.142, pp.676-685, 2008.

D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi et al., Somatic mutations of JAK2 exon 12 in patients with JAK2

, V617F)-negative myeloproliferative disorders, Blood, vol.111, pp.1686-1695, 2008.

Y. Yeh, Y. Chen, H. Cheng, W. Su, N. Chow et al., High percentage of JAK2 exon 12 mutation in asian patients with polycythemia vera, Am J Clin Pathol, vol.134, pp.266-70, 2010.

T. Mckerrell, N. Park, C. J. Collord, G. Moreno, T. Ponstingl et al., JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics, Blood Adv, vol.1, pp.968-71, 2017.

M. Gerstung, C. Jolly, I. Leshchiner, S. C. Dentro, S. Gonzalez et al., The evolutionary history of 2,658 cancers, Nature, vol.578, pp.122-130, 2020.

P. Blanche, J. Dartigues, and H. Jacqmin-gadda, Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks, Stat Med, vol.32, pp.5381-97, 2013.

A. Tefferi, E. Rumi, G. Finazzi, H. Gisslinger, A. M. Vannucchi et al., Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study, Leukemia, vol.27, pp.1874-81, 2013.

M. A. Lakey, A. Pardanani, J. D. Hoyer, P. L. Nguyen, T. L. Lasho et al., Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations, Am J Clin Pathol, vol.133, pp.942-950, 2010.